A phase Ill randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of Linagliptin (BI 1356) 2.5 mg + Metformin 500 mg or of Linagliptin(BI 1356) 2.5 mg + Metformin 1000 mg versus monotherapy with Metformin 1000 mgtwice daily over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46.

Category Primary study
Registry of TrialsClinical Trials Registry - India
Year 2010
This article has no abstract
Epistemonikos ID: ab2e559368d91c3d355233396b3c32eef566ae48
First added on: Apr 16, 2025